Web Annex E Examples of how to report diagnosis, start of treatment and treatment outcomes Consolidated guidance on tuberculosis data generation and use Module 1 Tuberculosis surveillance
Web Annex E Examples of how to report diagnosis, start of treatment and treatment outcomes Consolidated guidance on tuberculosis data generation and use Module 1 Tuberculosis surveillance Consolidated guidance on tuberculosis data generation and use. Module 1. Tuberculosis surveillance. Web Annex E. Examples of how to report diagnosis, start of treatment and treatment outcomes ISBN 978-92-4-008093-5 (electronic version) © World Health Organization 2024 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/ rules). Suggested citation. Web Annex E. Examples of how to report diagnosis, start of treatment and treatment outcomes. In: Consolidated guidance on tuberculosis data generation and use. Module 1: Tuberculosis surveillance. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see https://www.who.int/publications/book- orders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/ copyright. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third- party-owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. This publication forms part of the document entitled Consolidated guidance on tuberculosis data generation and use. Module 1. Tuberculosis surveillance. It is being made publicly available for transparency purposes and information. Scenario 1 1 Scenario 2 2 Scenario 3 3 Scenario 4 5 Scenario 5 7 Contents
1Scenario 1 Event Case-based record Weekly report Quarterly report Annual report A person is diagnosed with TB with no evidence of rifampicin resistance A record is added to the system describing the new case of TB The person is included in the count of people diagnosed with a new episode of TB (notified) in the week The person is included in the count of people diagnosed with TB (notified) in the quarter The person is included in the count of people diagnosed with TB (notified) in the year The person is started on first-line TB treatment The person’s case record is updated to include treatment details The person is included in the count of people started on TB treatment in the quarter The person is included in the count of people started on TB treatment in the year The person successfully completes TB treatment The person’s case record is updated with details of the successful outcome of treatment The person is included in the count of people successfully treated (for the quarter in which they started treatment) The person is included in the count of people successfully treated (for the year in which they started treatment) 1 week 6 months A person is diagnosed as having a new episode of TB, with no evidence of rifampicin resistance. The person starts first-line treatment one week after diagnosis. Six months later the person suc- cessfully completes TB treatment 21 week 12 months Event Case-based record Weekly report Quarterly report Annual report A person is diagnosed with rifampicin-resistant TB A record is added to the system describing the new case of TB The person is included in the count of people diagnosed with a new episode of TB (notified) in the week The person is included in the count of people diagnosed with TB (notified) in the quarter and also the number of people diagnosed with rifampicin-resistant TB in the quarter The person is included in the count of people diagnosed with TB (notified) in the year and also the number of people diagnosed with rifampicin-resistant TB in the year The person is started on treatment for rifampicin- resistant TB The person’s case record is updated to include treatment details The person is included in the count of people started on treatment for rifampicin-resistant TB in the year The person successfully completes rifampicin-resistant TB treatment The person’s case record is updated with details of the successful outcome of treatment The person is included in the count of people successfully treated (for the year in which they started treatment for rifampicin-resistant TB) Scenario 2 A person is diagnosed as having a new episode of TB which is rifampicin resistant. The person starts treatment for rifampicin-resistant TB one week after diagnosis. Twelve months later the per- son successfully completes treatment for rifampicin-resistant TB 3Event Case-based record Weekly report Quarterly report Annual report A person is diagnosed with TB with no evidence of rifampicin resistance A record is added to the system describing the new case of TB The person is included in the count of people diagnosed with a new episode of TB (notified) in the week The person is included in the count of people diagnosed with TB (notified) in the quarter The person is included in the count of people diagnosed with TB (notified) in the year The person is started on first-line TB treatment The person’s case record is updated to include treatment details The person is included in the count of people started on TB treatment in the quarter The person is included in the count of people started on TB treatment in the year Drug susceptibility test results show that the person has rifampicin-resistant TB First-line TB treatment is stopped The person’s case record is updated to include test results The person’s case record is updated to show failure of first-line TB treatment The person is included in the count of people with treatment failure (for the quarter in which they started treatment) The person is included in the count of people with treatment failure (for the year in which they started treatment) 1 week 2 months Part 1 First-line treatment for TB: Scenario 3 A person is diagnosed as having a new episode of TB. The person starts first-line treatment one week after diagnosis. Two months later drug susceptibility test results show that the person has TB resistant to rifampicin. The person’s first-line treatment is stopped and the person is started on treatment for rifampicin-resistant TB. Twelve months later the person successfully completes treatment for rifampicin-resistant TB 4Event Case-based record Weekly report Quarterly report Annual report The person is started on treatment for rifampicin- resistant TB A record is added to the system showing that the person has been re-registered and has started a new course of treatment for rifampicin-resistant TB The person is included in the count of people re-registered with TB in the year and also the number of people diagnosed with rifampicin-resistant TB in the year. The person is also included in the count of people started on treatment for rifampicin-resistant TB in the year The person successfully completes rifampicin-resistant TB treatment The person’s case record is updated with details of the successful outcome of treatment The person is included in the count of people successfully treated (for the year in which they started treatment for rifampicin-resistant TB) 12 months Part 2 Second-line treatment for rifampicin-resistant TB: 5Event Case-based record Weekly report Quarterly report Annual report A person is diagnosed with rifampicin-resistant TB A record is added to the system describing the new case of TB The person is included in the count of people diagnosed with a new episode of TB (notified) in the week The person is included in the count of people diagnosed with TB (notified) in the quarter and also the number of people diagnosed with rifampicin-resistant TB in the quarter The person is included in the count of people diagnosed with TB (notified) in the year and also the number of people diagnosed with rifampicin-resistant TB in the year The person is started on treatment for rifampicin- resistant TB The person’s case record is updated to include treatment details The person is included in the count of people started on treatment for rifampicin-resistant TB in the year The person shows signs of intolerance to the drugs and clinicians decide to change the regimen The person’s case record is updated to show failure of the RR- TB treatment The person is included in the count of people with treatment failure (for the year in which they started treatment) 1 week 8 weeks Part 1 Initial treatment regimen for RR-TB: Scenario 4 A person is diagnosed as having a new episode of TB which is rifampicin resistant. The person starts treatment for rifampicin-resistant TB one week after diagnosis. Eight weeks later the person shows signs of intolerance to the drugs used in the regimen and the clinicians treating the per- son decide to change the treatment regimen. Treatment using the initial regimen is stopped and treatment using an alternative regimen is started. Twelve months later the person successfully completes treatment for rifampicin-resistant TB using the alternative regimen 6Event Case-based record Weekly report Quarterly report Annual report The person is started on a changed treatment regimen for rifampicin- resistant TB A record is added to the system showing that the person has been re-registered and has started a new course of treatment for rifampicin-resistant TB The person is included in the count of people re-registered with TB in the year. The person is also included in the count of people started on treatment for rifampicin-resistant TB in the year in which the changed treatment was started The person successfully completes rifampicin-resistant TB treatment The person’s case record is updated with details of the successful outcome of treatment The person is included in the count of people successfully treated (for the year in which they started the changed treatment for rifampicin-resistant TB) 12 months Part 2: Changed treatment regimen for rifampicin-resistant TB: 7Event Case-based record Weekly report Quarterly report Annual report A person is diagnosed with rifampicin-resistant TB A record is added to the system describing the new case of TB The person is included in the count of people diagnosed with a new episode of TB (notified) in the week The person is included in the count of people diagnosed with TB (notified) in the quarter and also the number of people diagnosed with rifampicin-resistant TB in the quarter The person is included in the count of people diagnosed with TB (notified) in the year and also the number of people diagnosed with rifampicin-resistant TB in the year The person is started on treatment for rifampicin- resistant TB The person’s case record is updated to include treatment details The person is included in the count of people started on treatment for rifampicin-resistant TB in the year The person stops attending clinics With no contact in 2 months, clinicians decide the person is lost to follow up The person’s case record is updated with treatment outcome of lost to follow up The person is included in the count of people lost to follow up (for the year in which they started treatment for rifampicin-resistant TB) 1 week 2 months 3 months Scenario 5 A person is diagnosed as having a new episode of TB which is rifampicin resistant. The person starts treatment for rifampicin-resistant TB one week after diagnosis. Three months later the per- son stops attending clinics. The clinicians treating the person are not able to contact the person. Two months go by without any contact between the person and the clinicians. The person is re- corded as having been lost to follow-up For further information, please contact: Global Tuberculosis Programme World Health Organization 20, Avenue Appia CH-1211 Geneva 27 Switzerland Web site: www.who.int/tb